Preparation method and application of hydrogel microneedle and medicine storage cavern for treating nausea and vomiting

By preparing hydrogel microneedle plus drug storage, the side effects of fosapitant dimethylgluamine drug administration and insufficient drug delivery ability in nausea and vomiting of tumor patients were solved, and efficient transdermal administration was achieved and higher patient compliance, effectively prevent and treat nausea and vomiting symptoms.

CN119055580AInactive Publication Date: 2024-12-03ZHENGZHOU UNIV
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411235386.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-04
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Tumor patients often encounter nausea and vomiting during chemotherapy. The existing foxapitamdimethylgluamine drug in the form of intravenous injection has great side effects and poor patient compliance. The microneedle delivery system has limited drug delivery and drug release capabilities, making it difficult to be effective. Resolve nausea and vomiting symptoms.

Method used

The preparation method of hydrogel microneedle plus drug storage is prepared by mixing PDMS precursor with curing agent, and mixing it with fosapitant dimethylgluamine, PVP, sucrose and other ingredients. , lyophilized fosapitant dimethylgluamine lyophilized reservoir was prepared through ultrasonic treatment and freeze-drying technology, breaking through the space limitations of microneedle needles and achieving continuous large-dose administration.

Benefits of technology

The transdermal administration efficiency and patient compliance of fosapitantam dimethylgluamine were improved, effective prevention and treatment of nausea and vomiting symptoms were achieved, and a more convenient and efficient administration method was provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119055580A_ABST
    Figure CN119055580A_ABST
Patent Text Reader

Abstract

The invention relates to a preparation method and application of a hydrogel microneedle and drug reservoir for treating nausea and vomiting, and can effectively solve the problem that oral administration of tumor patients for nausea and vomiting is inconvenient, and the technical scheme for solving the problem is as follows: 1) preparing a PDMS microneedle female template; 2) preparing a hydrogel microneedle material solution with the mass fraction of 40%; 3) preparing a hydrogel microneedle solution; 4) preparing a blank hydrogel microneedle; 5) preparing the fosaprepitant dimeglumine freeze-dried storage cavern, the prepared fosaprepitant dimeglumine freeze-dried storage cavern can be effectively used for preventing and treating the nausea and vomiting symptoms of cancer patients, the anti-vomiting drug fosaprepitant dimeglumine is applied to a microneedle drug delivery system for the first time, drug delivery for the nausea and vomiting patients is more convenient, the compliance is higher, and the freeze-dried storage cavern can be used for preventing and treating the nausea and vomiting symptoms. The micro-needle drug delivery system is an innovation of a micro-needle drug delivery system.
Need to check novelty before this filing date? Find Prior Art

Description

1. Technical Field

[0001] The invention relates to the field of pharmaceutical preparations, in particular to a preparation method and application of a hydrogel microneedle plus a drug reservoir for treating nausea and vomiting. 2. Background Technology

[0002] Nausea and vomiting occur frequently in cancer patients. If medication to prevent vomiting is not given, 70%-80% of chemotherapy patients will experience nausea and vomiting; approximately 50%-80% of patients will experience nausea and vomiting during tumor radiotherapy; the incidence of postoperative nausea and vomiting ranges from 20% to 80%. There are many reasons for inducing nausea and vomiting in cancer patients, including not only gastrointestinal obstruction that may be caused by the tumor itself, but also side effects caused by tumor treatment. About 95% of patients will receive high / moderate emetogenic chemotherapy regimens. Cancer patients are mostly frail bedridden patients, and in the later stages they may not be able to eat normally due to worsening of their condition. Nausea and vomiting symptoms not only affect the patient's quality of life, but in severe cases can also cause water and electrolyte imbalance, lack of nutrition, and affect the patient's treatment effect. Most patients also receive antiemetic treatment while receiving chemotherapy.

[0003] Fosaprepitant dimeglumine is a drug used to prevent and treat chemotherapy-induced nausea and vomiting. It is a NK1 receptor antagonist. The drug interferes with the chemical stimulation conduction pathway caused by chemotherapy by binding to the NK1 receptor and blocking its activity, thereby reducing the sensitivity to stimuli that trigger nausea and vomiting reactions. Fosaprepitant dimeglumine is usually administered in the form of intravenous injection, which can lead to problems such as large side effects and poor patient compliance.

[0004] As a new type of transdermal drug delivery method, microneedles break through the skin stratum corneum barrier in a minimally invasive and painless way, and can directly deliver drugs to the target site on the skin surface, avoiding the first-pass effect of drugs, enhancing patient compliance and achieving efficient and convenient drug delivery. However, due to the small space of the microneedle body, its drug loading and release capacity is limited. Hydrogel microneedles are made of swellable polymer materials. After piercing the skin in a glassy state, they absorb the skin interstitial fluid and transform into a hydrogel state, forming an unobstructed hydrogel channel in the skin. Hydrogel microneedles can be used in conjunction with drug reservoirs to break through the limitations of the limited space of the microneedle body and achieve continuous high-dose administration. Therefore, the development of a microneedle drug delivery system loaded with fosaprepitant dimeglumine to treat nausea and vomiting, improve the efficiency of transdermal drug delivery, and improve patient compliance has broad therapeutic prospects. III. Summary of the invention

[0005] In view of the above situation, in order to solve the defects of the prior art, the purpose of the present invention is to provide a preparation method and application of hydrogel microneedles plus drug reservoirs for the treatment of nausea and vomiting, which can effectively solve the problem of inconvenience of oral medication for nausea and vomiting in tumor patients.

[0006] The technical solution provided by the present invention is that the preparation method of the hydrogel microneedle plus drug reservoir for treating nausea and vomiting comprises the following steps:

[0007] 1) Stir and mix the PDMS precursor (Sylgard184) and the curing agent in a mass ratio of 10:1, inject into the container containing the microneedle positive mold, wait for the bubbles to disappear, place at 37°C for 24-48 hours to completely cure, separate the microneedle positive mold and PDMS after curing, and obtain the PDMS microneedle negative template;

[0008] 2) At room temperature, prepare a 40% mass fraction of hydrogel microneedle material solution, stir it evenly and store it at 4°C;

[0009] 3) dissolving the hydrogel microneedle material in ultrapure water, and then mixing it with the hydrogel microneedle material solution prepared in step 2), stirring evenly to obtain a hydrogel microneedle solution; in the hydrogel microneedle solution, the mass fraction of the hydrogel microneedle material is 20%, and the mass fraction of the hydrogel microneedle material is 7.5%;

[0010] 4) adding the hydrogel microneedle solution prepared in step 3) to the PDMS microneedle negative template prepared in step 1), centrifuging at 3500-5000 r / min for 5-10 min, drying at 37° C. for 24-48 h, then crosslinking in an oven at 80-120° C. for 24-48 h, and demolding to obtain blank hydrogel microneedles;

[0011] 5) 10 mg of fosaprepitant dimeglumine, 3 mg of PVP, 4 mg of sucrose excipient and 1 ml of water were added to a centrifuge tube and mixed evenly; then, ultrasonic treatment was performed at 20-30° C. and 60-80 Hz for 10-30 min to obtain a formula solution; the formula solution was cast into the blank hydrogel microneedle mold prepared in step 4), pre-frozen at -70 to -100° C. for 1-3 h, and then transferred to a cold -50 to -70° C. and a vacuum degree of 10-20 Pa, and freeze-dried for 20-30 h; after drying, the mixture was peeled off from the mold to obtain a fosaprepitant dimeglumine freeze-dried reservoir.

[0012] The blank hydrogel microneedle is an array consisting of one or more microneedles, the length of the microneedle is 50-5000 μm, and is used to pierce the skin stratum corneum barrier and deliver fosaprepitant dimeglumine transdermally.

[0013] In the step 2), the solvent in the material solution of the hydrogel microneedle is a mixture of one or more of water, ethanol, acetic acid, dimethyl sulfoxide, ethyl acetate, glycerol, ethylenediamine, and cyclohexane.

[0014] In the step 2), the material of the hydrogel microneedle includes a mixture of one or more of methyl vinyl ether-maleic anhydride (Gantrez), methacrylic polymers, PVA-PVP crosslinkers, methyl vinyl ether-maleic anhydride copolymers (PMVE / MAH), poly(methyl vinyl ether maleic acid) (PMVE / MA) and PEG, methacryloyl hyaluronic acid, polyethylene glycol diacrylate (PEGDA) hydrogel, etc.

[0015] In the step 3), the hydrogel microneedle material includes but is not limited to PEG200, PEG6000, PEG10000, monomer polymers or copolymers of polyvinyl alcohol, PVA, PVP and their derivatives, hyaluronic acid, gelatin, dextrin, cyclodextrin derivatives, dextran, mannitol, acetate, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, chondroitin, dextran, sucrose, chitosan, sodium alginate, pullulan, maltose, lactose, pullulan, methacryloyl hyaluronic acid, polyethylene glycol diacrylate (PEGDA), and a mixture of one or more copolymers.

[0016] Application of the fosaprepitant dimeglumine freeze-dried reservoir prepared by the invention in medicine for preventing and treating nausea and vomiting symptoms of cancer patients.

[0017] The hydrogel microneedle plus drug reservoir (fosaprepitant dimeglumine lyophilized reservoir) prepared by the present invention can be effectively used to prevent and treat nausea and vomiting symptoms in cancer patients. It is the first time that the antiemetic drug fosaprepitant dimeglumine has been applied to a microneedle drug delivery system. It is more convenient to administer the drug to patients with nausea and vomiting, and has higher compliance. It is an innovation in the microneedle drug delivery system. IV. Description of the drawings

[0018] Figure 1 Schematic diagram of blank hydrogel microneedles prepared in Example 1 of the present invention.

[0019] Figure 2 Schematic diagram of blank hydrogel microneedles prepared in Example 2 of the present invention.

[0020] Figure 3 This is a graph of the swelling rate of the blank hydrogel microneedles prepared in Examples 1 and 2 of the present invention.

[0021] Figure 4 This is a diagram of the equilibrium water content of the blank hydrogel microneedles prepared in Examples 1 and 2 of the present invention.

[0022] Figure 5 This is a freeze-dried drug reservoir diagram of fosaprepitant dimeglumine prepared in the present invention, comprising 10 mg fosaprepitant dimeglumine + 3 mg PVP + 1 ml water.

[0023] Figure 6 This is a freeze-dried drug reservoir diagram of fosaprepitant dimeglumine prepared in the present invention, comprising 10 mg fosaprepitant dimeglumine + 4 mg PVP + 1 ml water.

[0024] Figure 7 This is a freeze-dried drug reservoir diagram of fosaprepitant dimeglumine prepared in the present invention, comprising 10 mg fosaprepitant dimeglumine + 3 mg PVP + 2 mg sucrose + 1 ml water.

[0025] Figure 8 This is a freeze-dried drug reservoir diagram of fosaprepitant dimeglumine prepared in the present invention, comprising 10 mg fosaprepitant dimeglumine + 3 mg PVP + 4 mg sucrose + 1 ml water.

[0026] Fig. 9 Schematic diagram of the in vitro release curve of the hydrogel microneedles plus freeze-dried drug reservoir prepared in Example 1 of the present invention.

[0027] Fig.10 Schematic diagram of the in vitro release curve of the hydrogel microneedles plus freeze-dried drug reservoir prepared in Example 2 of the present invention. V. Specific implementation methods

[0028] The specific implementation modes of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0029] Example 1

[0030] The present invention, when implemented, specifically comprises the following steps:

[0031] 1) The PDMS precursor (Sylgard184) and the curing agent were stirred and mixed at a mass ratio of 10:1, and injected into a container containing a positive microneedle mold (microneedle length of 850 μm). After the bubbles were eliminated, the mold was placed at 37°C for 24 h to completely cure. After curing, the positive microneedle mold and PDMS were separated to obtain a negative PDMS microneedle mold;

[0032] 2) At room temperature, prepare a 40% by mass methyl vinyl ether-maleic anhydride solution, stir it evenly and store it at 4°C;

[0033] 3) dissolving PEG10000 in ultrapure water, and then mixing with the methyl vinyl ether-maleic anhydride solution prepared in step 2), stirring evenly to obtain a hydrogel microneedle solution; in the hydrogel microneedle solution, the mass fraction of the hydrogel microneedle material is 20%, and the mass fraction of PEG10000 is 7.5%;

[0034] 4) adding the hydrogel microneedle solution prepared in step 3) to the PDMS microneedle negative template prepared in step 1), centrifuging at 5000 r / min for 5 min, drying at 37° C. for 24 h, and then crosslinking in an oven at 80° C. for 24 h, and demolding to obtain blank hydrogel microneedles;

[0035] 5) 10 mg of fosaprepitant dimeglumine, 3 mg of PVP, 4 mg of sucrose excipient and 1 ml of water were added to a centrifuge tube and mixed evenly; then, ultrasonic treatment was performed at 20° C. with an ultrasonic power of 60 Hz for 10 min to obtain a formula solution; the formula solution was cast into the blank hydrogel microneedle mold prepared in step 4), pre-frozen at -70° C. for 1 h, and then transferred to a cold -50° C., a vacuum degree of 10 Pa, and freeze-dried for 20 h; after drying, it was peeled off from the mold to obtain a fosaprepitant dimeglumine freeze-dried reservoir.

[0036] The blank hydrogel microneedles prepared in this example are Figure 1 As shown, the appearance is complete and the needle tip is in good shape. Figure 3 , 4 It can be seen that the microneedle swelling rate reached a maximum of 1330.74% in two hours, and its equilibrium water content was 94.1033%.

[0037] Example 2

[0038] The present invention, when implemented, specifically comprises the following steps:

[0039] 1) The PDMS precursor (Sylgard184) and the curing agent were stirred and mixed at a mass ratio of 10:1, and injected into a container containing a positive microneedle mold (microneedle length of 850 μm). After the bubbles were eliminated, the mold was placed at 37°C for 24 h to completely cure. After curing, the positive microneedle mold and PDMS were separated to obtain a negative PDMS microneedle mold;

[0040] 2) At room temperature, prepare a 40% PVA-PVP crosslinking solution, stir it evenly and store it at 4°C;

[0041] 3) dissolving PVA in ultrapure water, and then mixing with the PVA-PVP crosslinking solution prepared in step 2), stirring evenly to obtain a hydrogel microneedle solution; in the hydrogel microneedle solution, the mass fraction of the hydrogel microneedle material is 20%, and the mass fraction of the PVA-PVP crosslinking product is 7.5%;

[0042] 4) adding the hydrogel microneedle solution prepared in step 3) to the PDMS microneedle negative template prepared in step 1), centrifuging at 3500 r / min for 5 min, drying at 37° C. for 48 h, and then crosslinking in an oven at 80° C. for 24 h, and demolding to obtain blank hydrogel microneedles;

[0043] 5) 10 mg of fosaprepitant dimeglumine, 3 mg of PVP, 4 mg of sucrose excipient and 1 ml of water were added to a centrifuge tube and mixed evenly; then, ultrasonic treatment was performed at 25° C. with an ultrasonic power of 70 Hz for 20 min to obtain a formula solution; the formula solution was cast into the blank hydrogel microneedle mold prepared in step 4), pre-frozen at -85° C. for 2 h, and then transferred to a cold -60° C., a vacuum degree of 15 Pa, and freeze-dried for 25 h; after drying, it was peeled off from the mold to obtain a fosaprepitant dimeglumine freeze-dried reservoir.

[0044] The hydrogel microneedles prepared in this embodiment are as follows Figure 2 As shown, the appearance is complete and the needle tip is in good shape. Figure 3 , 4 It can be seen that the microneedle swelling rate reached a maximum of about 449.27% ​​in 2 hours, and its equilibrium water content was 77.73%.

[0045] The lyophilized reservoir of fosaprepitant dimeglumine of the present invention breaks through the limitation of the limited space of the microneedle body, realizes continuous large-dose drug delivery, can effectively improve the efficiency of transdermal drug delivery, and improve patient compliance. The relevant test data are as follows:

[0046] 1. Screening of freeze-dried drug reservoir formula of fosaprepitant dimeglumine

[0047] Take fosaprepitant dimeglumine, excipients and water and add them into a centrifuge tube (a total of four formulas were selected for screening: 10 mg fosaprepitant dimeglumine + 3 mg PVP + 1 ml water, 10 mg fosaprepitant dimeglumine + 4 mg PVP + 1 ml water, 10 mg fosaprepitant dimeglumine + 3 mg PVP + 2 mg sucrose + 1 ml water and 10 mg fosaprepitant dimeglumine + 3 mg PVP + 4 mg sucrose + 1 ml water.), mix uniform; then at 20-30°C, ultrasonic power is 60-80Hz, ultrasonic treatment is carried out for 10-30min to obtain a formula solution; the formula solution is cast into a blank hydrogel microneedle mold, pre-frozen at -70 to -100°C for 1-3h, and then transferred to a cold -50 to -70°C, vacuum degree 10-20Pa, freeze-dried for 20-30h; after drying, the freeze-dried reservoir is peeled off from the mold to obtain the fosaprepitant dimeglumine freeze-dried reservoir.

[0048] The test results are as follows Figure 5-8 As shown, the first three reservoirs are too dispersed and are not suitable for drug reservoirs; the drug reservoir made with 10 mg fosaprepitant dimeglumine + 3 mg PVP + 4 mg sucrose + 1 ml water is evenly dispersed and has a certain toughness, so this formula is selected.

[0049] 2. Study on the Transdermal Release of Microneedles Prepared in Example 1 Using a Vertical Franz Diffusion Cell

[0050] 8 mL of PBS solution (pH 7.4) was added to the receiving chamber of the Franz diffusion cell as the receiving solution, and magnetic stirring was performed at 750 r / min in a constant temperature water bath at 37 ° C. The ex vivo C57 mouse skin was treated and trimmed to a shape suitable for the Franz diffusion cell. Then the microneedle and drug reservoir were placed in the center of the mouse skin, and the microneedle was inserted into the skin by pressing for 30 seconds. A stainless steel cylinder (diameter 16.6 mm, mass 12.0 g) was placed on the top of each microneedle to keep the microneedle and the skin in full contact. The skin with the inserted microneedle was placed between the supply chamber and the receiving chamber, and the bubbles were discharged so that the receiving medium liquid surface was in full contact with the mouse skin. 200 μL of the receiving solution was taken from the receiving chamber at 1, 2, 3, 4, 5, 6, 8, and 24 h, and 200 μL of PBS solution (pH 7.4) was added to the receiving chamber. After 24 hours of application, the microneedles were removed, and the mouse skin was taken to make skin homogenate. The skin homogenate and the taken receptor fluid were centrifuged at 3000r / min for 10 minutes, and the supernatant was measured by high performance liquid chromatography for the concentration of fosaprepitant dimeglumine. The experiment was carried out in parallel three times, and the release curve was drawn with the cumulative release amount as the ordinate and the release time as the abscissa.

[0051] The drug reservoir loading capacity is about 9.08 mg. Fig. 9 As shown, after 24 hours, the cumulative drug release of PVP+PVA+CA hydrogel microneedles plus drug reservoir was 113.759±18.264μg, accounting for 1.25% of the total drug amount; the cumulative drug released in the skin was 2642.792±2873.494μg, accounting for 57.60% of the total drug amount.

[0052] 3. Study on the Transdermal Release of Microneedles Prepared in Example 2 Using Vertical Franz Diffusion Cell

[0053] 8 mL of PBS solution (pH 7.4) was added to the receiving chamber of the Franz diffusion cell as the receiving solution, and magnetic stirring was performed at 750 r / min in a constant temperature water bath at 37 ° C. The ex vivo C57 mouse skin was treated and trimmed to a shape suitable for the Franz diffusion cell. Then the microneedle and drug reservoir were placed in the center of the mouse skin, and the microneedle was inserted into the skin by pressing for 30 seconds. A stainless steel cylinder (diameter 16.6 mm, mass 12.0 g) was placed on the top of each microneedle to keep the microneedle and the skin in full contact. The skin with the inserted microneedle was placed between the supply chamber and the receiving chamber, and the bubbles were discharged so that the receiving medium liquid surface was in full contact with the mouse skin. 200 μL of the receiving solution was taken from the receiving chamber at 1, 2, 3, 4, 5, 6, 8, and 24 h, and 200 μL of PBS solution (pH 7.4) was added to the receiving chamber. After 24 hours of application, the microneedles were removed, and the mouse skin was taken to make skin homogenate. The skin homogenate and the taken receptor fluid were centrifuged at 3000r / min for 10 minutes, and the supernatant was measured by high performance liquid chromatography for the concentration of fosaprepitant dimeglumine. The experiment was carried out in parallel three times, and the release curve was drawn with the cumulative release amount as the ordinate and the release time as the abscissa.

[0054] The drug reservoir loading capacity is about 9.08 mg. Fig.10 As shown, the cumulative drug release of Gantrez+PEG10000 microneedles in 24 hours was 108.921±39.096μg, accounting for 1.20% of the total drug amount; the cumulative drug release in the skin was 1012.368±1028.633μg, accounting for 11.14% of the total drug amount.

[0055] After repeated tests and practices, other embodiments have obtained the same or similar test results as the above embodiment, which will not be described in detail one by one.

[0056] In the lyophilized reservoir of fosaprepitant dimeglumine of the present invention, the hydrogel microneedles can form tiny channels on the skin surface to promote the transdermal absorption of the drug, while the lyophilized drug reservoir can achieve continuous drug delivery. The combination of the two can achieve more efficient drug delivery, greatly improve the transdermal release efficiency of the drug, and has good promotion and application value.

[0057] It should be pointed out that the above is only a preferred embodiment of the present invention and does not limit the present invention in any form. Any technician familiar with the profession can make changes or modify the technical contents disclosed above into equivalent embodiments with equivalent changes without departing from the scope of the technical solution of the present invention, which all fall within the protection scope of the present invention.

Claims

1. A method for preparing a hydrogel microneedle plus a drug reservoir for treating nausea and vomiting, characterized in that: The following steps are involved: 1) Stir and mix the PDMS precursor Sylgard184 and the curing agent in a mass ratio of 10:1, inject into the container containing the microneedle positive mold, wait for the bubbles to disappear, place at 37 ° C for 24-48 hours to completely cure, separate the microneedle positive mold and PDMS after curing, and obtain the PDMS microneedle negative template; 2) At room temperature, prepare a 40% mass fraction hydrogel microneedle material solution, stir it evenly and store it at 4°C; 3) dissolving the hydrogel microneedle material in ultrapure water, and then mixing it with the hydrogel microneedle material solution prepared in step 2), stirring evenly to obtain a hydrogel microneedle solution; in the hydrogel microneedle solution, the mass fraction of the hydrogel microneedle material is 20%, and the mass fraction of the hydrogel microneedle material is 7.5%; 4) adding the hydrogel microneedle solution prepared in step 3) to the PDMS microneedle negative template prepared in step 1), centrifuging at 3500-5000 r / min for 5-10 min, drying at 37°C for 24-48 h, and then crosslinking in an oven at 80-120°C for 24-48 h, and demolding to obtain blank hydrogel microneedles; 5) Take 10 mg of fosaprepitant dimeglumine, 3 mg of PVP, 4 mg of sucrose excipient and 1 ml of water and add them to a centrifuge tube and mix them evenly; then, ultrasonically treat for 10-30 min at 20-30°C and an ultrasonic power of 60-80 Hz to obtain a formula solution; cast the formula solution into the blank hydrogel microneedle mold prepared in step 4), pre-freeze at -70 to -100°C for 1-3h, and then transfer to a cold -50 to -70°C and a vacuum degree of 10-20 pa, and freeze-dry for 20-30h; after drying, peel it off from the mold to obtain a fosaprepitant dimeglumine freeze-dried reservoir.

2. The method for preparing the hydrogel microneedle plus drug reservoir for treating nausea and vomiting according to claim 1, characterized in that: The blank hydrogel microneedles are an array consisting of one or more microneedles, and the length of the microneedles is 50-5000 μm.

3. The method for preparing the hydrogel microneedle plus drug reservoir for treating nausea and vomiting according to claim 1, characterized in that: In the step 2), the solvent in the material solution of the hydrogel microneedle is a mixture of one or more of water, ethanol, acetic acid, dimethyl sulfoxide, ethyl acetate, glycerol, ethylenediamine, and cyclohexane.

4. The method for preparing the hydrogel microneedle plus drug reservoir for treating nausea and vomiting according to claim 1, characterized in that: In the step 2), the material of the hydrogel microneedle is a mixture of one or more of methyl vinyl ether-maleic anhydride, methacrylic polymer, PVA-PVP crosslinker, methyl vinyl ether-maleic anhydride copolymer, poly(methyl vinyl ether maleic acid) and PEG, methacryloyl hyaluronic acid, and polyethylene glycol diacrylate hydrogel.

5. The method for preparing the hydrogel microneedle plus drug reservoir for treating nausea and vomiting according to claim 1, characterized in that: In the step 3), the hydrogel microneedle material is a mixture of one or more of PEG200, PEG6000, PEG10000, monomer polymers or copolymers of polyvinyl alcohol, PVA, PVP and their derivatives, hyaluronic acid, gelatin, dextrin, cyclodextrin derivatives, dextran, mannitol, acetate, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, microcrystalline cellulose, chondroitin, dextran, sucrose, chitosan, sodium alginate, pullulan, maltose, lactose, pullulan, methacryloyl hyaluronic acid, polyethylene glycol diacrylate (PEGDA), and copolymers.

6. Use of the lyophilized reservoir of fosaprepitant dimeglumine prepared by the preparation method according to any one of claims 1 to 5 in a drug for preventing and treating nausea and vomiting symptoms in cancer patients.

Citation Information

Patent Citations

  • Sterile lyophilized preparation containing fosaprepitant, and preparation method thereof

    CN102755296A

  • Use of neurokinin-1 antagonists to treat a variety of pruritic conditions

    CN109640981A

  • Hydrogel microneedle with replaceable drug-loading reservoir and preparation method of hydrogel microneedle

    CN115154883A

  • Apparatus and method for transdermal delivery of a 5-hydroxytrytamine antagonist

    WO2008115599A1